Effects of antipsychotics on bone mineral density and prolactin levels in patients with schizophrenia: A 12-month prospective study

Human Psychopharmacology

Volumn 29, Issue 2, 2014, Pages 183-189

  Wang, Mengxin ^a   Hou, Ruihua ^b   Jian, Jia ^c   Mi, Guolin ^c   Qiu, Huimin ^c   Cao, Bingyu ^c   Tang, Maoqin ^c  

^a SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c Shandong Mental Health Center   (China)

Author keywords

bone mineral density; conventional atypical antipsychotics; prolactin; schizophrenia

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CHLORPROMAZINE; CLOZAPINE; ESTROGEN; NEUROLEPTIC AGENT; PERPHENAZINE; PROLACTIN; QUETIAPINE; SULPIRIDE; TRIHEXYPHENIDYL; ALKALINE PHOSPHATASE; DIBENZOTHIAZEPINE DERIVATIVE; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DRUG EFFECT; EVENING DOSAGE; FEMALE; FOLLOW UP; HOSPITAL PATIENT; HUMAN; INTERVENTION STUDY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRESCRIPTION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SINGLE DRUG DOSE; TREATMENT DURATION; TREATMENT OUTCOME; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; OSTEOPOROSIS; PATHOPHYSIOLOGY; RISK FACTOR;

ADULT; ALKALINE PHOSPHATASE; ANTIPSYCHOTIC AGENTS; BONE DENSITY; CHLORPROMAZINE; CLOZAPINE; DIBENZOTHIAZEPINES; ESTROGENS; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; PERPHENAZINE; PIPERAZINES; PROLACTIN; PROSPECTIVE STUDIES; QUINOLONES; RISK FACTORS; SCHIZOPHRENIA; SULPIRIDE;

EID: 84895530283     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2387     Document Type: Article

References (39)

1. Alldredge BK, Kimble K, Anne M, Lloyd Y, Kradjan WA, Guglielmo BJ,. 2009. Applied Therapeutics: The Clinical use of Drugs. Wolters Kluwer Health/Lippincott Williams & Wilkins: Philadelphia.
2. Ataya K, Mercado A, Kartaginer J, Abbasi A, Moghissi KS,. 1988. Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia. Fertil Steril 50: 876-881.
3. Bradford PG, Gerace KV, Roland RL, Chrzan BG,. 2010. Estrogen regulation of apoptosis in osteoblasts. Physiol Behav 99: 181-185.
4. Emiliano AB, Fudge JL,. 2004. From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions. Neuropsychopharmacology 29: 833-846.
5. Goodman SB, Jiranek W, Petrow E, Yasko AW,. 2007. The effects of medications on bone. J Am Acad Orthop Surg 15: 450-460.
6. Graham SM, Howgate D, Anderson W, et al,. 2011. Risk of osteoporosis and fracture incidence in patients on antipsychotic medication. Expert Opin Drug Saf 10: 575-602.
7. Halbreich U,. 2007. Osteoporosis, schizophrenia and antipsychotics: the need for a comprehensive multifactorial evaluation. CNS Drugs 21: 641-657.
8. Halbreich U, Kahn LS,. 2003. Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J Psychiatr Pract 9: 344-353.
9. Howard L, Kirkwood G, Leese M,. 2007. Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry 190: 129-134.
10. Hummer M, Huber J,. 2004. Hyperprolactinaemia and antipsychotic therapy in schizophrenia. Curr Med Res Opin 20: 189-197.
11. Javaid MK, Holt RI,. 2008. Understanding osteoporosis. J Psychopharmacol 22: 38-45.
12. Kameda T, Mano H, Yuasa T, et al,. 1997. Estrogen inhibits bone resorption by directly inducing apoptosis of the bone-resorbing osteoclasts. J Exp Med 186: 489-495.
13. Kaneda Y, Kawamura I, Fujii A, Ohmori T,. 2004. Impact of a switch from typical to atypical antipsychotic drugs on quality of life and gonadal hormones in male patients with schizophrenia. Neuro Endocrinol Lett 25: 135-140.
14. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N,. 2008. A reference standard for the description of osteoporosis. Bone 42: 467-475.
15. Kay SR, Opler LA, Lindenmayer JP,. 1988. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 23: 99-110.
16. Kishimoto T, Watanabe K, Takeuchi H, et al,. 2005. Bone mineral density measurement in female inpatients with schizophrenia. Schizophr Res 77: 113-115
17. Krum SA, Brown M,. 2008. Unraveling estrogen action in osteoporosis. Cell Cycle 7: 1348-1352.
18. Lee TY, Chung MY, Chung HK, Choi JH, Kim TY, So HS,. 2010. Bone density in chronic schizophrenia with long-term antipsychotic treatment: preliminary study. Psychiatry Investig 7: 278-284.
19. Lieberman JA, Stroup TS, McEvoy JP,. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
20. McGrath J, Saha S, Chant D, Welham J,. 2008. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 30: 67-76.
21. Meaney AM, Smith S, Howes OD, O'Brien M, Murray RM, O'Keane V,. 2004. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 184: 503-508.
22. Molitch ME,. 2005. Medication-induced hyperprolactinemia. Mayo Clin Proc 80: 1050-1057.
23. Montejo AL,. 2008. Prolactin awareness: an essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol 18: S108-S114.
24. Montgomery J, Winterbottom E, Jessani M, et al,. 2004. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry 65: 1491-1498.
25. Partti K, Heliövaara M, Impivaara O, et al,. 2010. Skeletal status in psychotic disorders: a population-based study. Psychosom Med 72: 933-940.
26. Petty RG,. 1999. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res 35: S67-S73.
27. Peveler RC, Branford D, Citrome L, et al,. 2008. Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychopharmacol 22: 98-103.
28. Renn JH, Yang NP, Chueh CM, Lin CY, Lan TH, Chou P,. 2009. Bone mass in schizophrenia and normal populations across different decades of life. BMC Musculoskelet Disord 10: 1.
29. Renn JH, Yang NP, Chou P,. 2010. Effects of plasma magnesium and prolactin on quantitative ultrasound measurements of heel bone among schizophrenic patients. BMC Musculoskelet Disord 11: 35.
30. Rey-Sánchez P, Lavado-García JM, Canal-Macías ML, Gõmez-Zubeldia MA, Roncero-Martín R, Pedrera- Zamorano JD,. 2009. Ultrasound bone mass in schizophrenic patients on antipsychotic therapy. Hum Psychopharmacol 24: 49-54.
31. Riecher-Rössler A, Schmid C, Bleuer S, Birkhäuser M,. 2009. Antipsychotics and hyperpolactinaemia: pathophysiology, clinical relevance, diagnosis and therapy. Neuropsychiatr 23: 71-83.
32. Roke Y, van Harten PN, Boot AM, Buitelaar JK,. 2009. Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects. J Child Adolesc Psychopharmacol 19: 403-414.
33. Sugawara N, Yasui-Furukori N, Fujii A, et al,. 2011. No association between bone mass and prolactin levels among patients with schizophrenia. Hum Psychopharmacol 26: 596-601.
34. Van Os J, Kapur S,. 2009. Schizophrenia. Lancet 374: 635-645.
35. Wahlbeck K, Tuunainen A, Ahokas A, Leucht S,. 2001. Dropout rates in randomized antipsychotic drug trials. Psychopharmacology (Berl) 155: 230-233.
36. Walters J, Jones I,. 2008. Clinical questions and uncertainty-prolactin measurement in patients with schizophrenia and bipolar disorder. J Psychopharmacol 22: 82-89.
37. World Health Organization. 1994. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of WHO Study Group.
38. World Health Organization. 2004. World Health Organization scientific group on the assessment of osteoporosis at the primary health care level. Summary Meeting Report. Brussels.
39. World Health Organization. 2011. Schizophrenia. Available at: (http://www.who.int/mental-health/management/schizophrenia/en/) Assessed 26 February 2013